

NCT ID	NCT02997228
Title	Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study
Phase	Phase 3
Date Added	2016-12-20
Location	Arizona, United States Arkansas, United States California, United States Colorado, United States Connecticut, United States Delaware, United States District of Columbia, United States Florida, United States Georgia, United States Idaho, United States Illinois, United States Indiana, United States Iowa, United States Kansas, United States Kentucky, United States Louisiana, United States Maine, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Mississippi, United States Missouri, United States Montana, United States Nebraska, United States Nevada, United States New Hampshire, United States New Jersey, United States New Mexico, United States New York, United States North Carolina, United States North Dakota, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States South Carolina, United States South Dakota, United States Tennessee, United States Texas, United States Utah, United States Vermont, United States Virginia, United States Washington, United States West Virginia, United States Wisconsin, United States Wyoming, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Atezolizumab, fluorouracil, Leucovorin, oxaliplatin
Tags	MSI-H/ MMRd

NCT ID	NCT02988960
Title	A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors
Phase	Phase 1
Date Added	2016-12-12

Location	California, United States Illinois, United States Massachusetts, United States North Carolina, United States Tennessee, United States Texas, United States Virginia, United States Australia Canada France Japan Korea, Republic of Spain
Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	ABBV-181, ABBV-927, Opdivo
Tags	MSS/ MMRp
NCT ID	NCT02925234
Title	The Drug Rediscovery Protocol (DRUP Trial)
Phase	Phase 2
Date Added	2016-10-05
Location	Netherlands
Prior IO Allowed	Yes
CRC-directed	No
Status	Recruiting
Drugs	Abemaciclib, afatinib, Alectinib, Alpelisib, Atezolizumab and Bevacizumab, Axitinib, Cabozantinib, Crizotinib, Dabrafenib, Dabrafenib and trametinib, Dacomitinib, durvalumab, Entrectinib, Erdafitinib, Erlotinib, Ipilimumab and nivolumab, Lenvatinib, lorlatinib, Nilotinib, Nivolumab, Olaparib, palbociclib, panitumumab, Pembrolizumab, Regorafenib, ribociclib, Rucaparib, Sunitinib, Talazoparib, Trametinib, Trastuzumab and Pertuzumab (combination treatment), Vemurafenib and Cobimetinib (combination treatment), Vismodegib
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT02888743
Title	Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer
Phase	Phase 2
Date Added	2016-09-05
Location	Arizona, United States California, United States Connecticut, United States Florida, United States Georgia, United States Kentucky, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Missouri, United States New Jersey, United States North Carolina, United States Ohio, United States Pennsylvania, United States Tennessee, United States Virginia, United States Wisconsin, United States Canada
Prior IO Allowed	Yes

CRC-directed	Yes
Status	Active, not recruiting
Drugs	durvalumab, Tremelimumab
Tags	MSS/ MMRp
NCT ID	NCT02886585
Title	Pembrolizumab In Central Nervous System Metastases
Phase	Phase 2
Date Added	2016-09-01
Location	Massachusetts, United States
Prior IO Allowed	No
CRC-directed	No
Status	Active, not recruiting
Drugs	Pembrolizumab
Tags	MSS/ MMRp
NCT ID	NCT02869217
Title	Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors
Phase	Phase 1
Date Added	2016-08-16
Location	Canada
Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	Cyclophosphamide, Fludarabine, TBI-1301
Tags	MSS/ MMRp
NCT ID	NCT02864485
Title	Living Donor Liver Transplantation for Unresectable Colorectal Cancer Liver Metastases
Phase	Not Applicable
Date Added	2016-08-12
Location	Canada
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT02856425
Title	Trial Of Pembrolizumab And Nintedanib
Phase	Phase 1
Date Added	2016-08-04
Location	France
Prior IO Allowed	No
CRC-directed	No
Status	Recruiting
Drugs	Nintedanib, Pembrolizumab, Keytruda, Ofev, Vargatef
Tags	MSS/ MMRp
NCT ID	NCT02693535

Title	TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Phase	Phase 2
Date Added	2016-02-26
Location	Alabama, United States Arizona, United States California, United States Connecticut, United States Florida, United States Georgia, United States Hawaii, United States Illinois, United States Indiana, United States Maine, United States Michigan, United States Nebraska, United States New Hampshire, United States New Mexico, United States New York, United States North Carolina, United States North Dakota, United States Ohio, United States Oregon, United States Pennsylvania, United States South Carolina, United States South Dakota, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Washington, United States Wisconsin, United States
Prior IO Allowed	Yes
CRC-directed	No
Status	Recruiting
Drugs	Abemaciclib, afatinib, Atezolizumab and PHESGO, Atezolizumab and Talazoparib, Crizotinib, Entrectinib, Larotrectinib, Nivolumab and Ipilimumab, Olaparib, palbociclib, Pembrolizumab, Regorafenib, Sunitinib, Talazoparib, Temsirolimus, Trastuzumab and Pertuzumab, Tucatinib plus Trastuzumab Subcutaneous (SC), Vemurafenib and Cobimetinib, Cotellic, Herceptin, Perjeta, Zelboraf
Tags	MSI-H/ MMRd, MSS/ MMRp

NCT ID	NCT02675946
Title	CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)
Phase	Phase 1
Date Added	2016-02-05

Location	California, United States
	Colorado, United States
	Connecticut, United States
	District of Columbia, United States
	Florida, United States
	Georgia, United States
	Hawaii, United States
	Illinois, United States
	Indiana, United States
	Maryland, United States
	Massachusetts, United States
	Nebraska, United States
	New Jersey, United States
	North Carolina, United States
	Pennsylvania, United States
	South Dakota, United States
	Tennessee, United States
	Texas, United States
	Washington, United States
	Wisconsin, United States
	Taiwan
Prior IO Allowed	No
CRC-directed	No
Status	Recruiting
Drugs	cetuximab, CGX1321, encorafenib, Pembrolizumab, Keytruda
Tags	MSS/ MMRp